16 March 2018
�
�
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
�
Director/PDMR Shareholding
�
�
Allergy Therapeutics�(AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 15 March 2018, Tunde Otulana, Non-Executive Director of the Company, purchased 25,000 ordinary shares of 0.1p in the Company ("Ordinary Shares") at a price of $0.388 per Ordinary Share (equivalent to 27.8p per Ordinary Share)*. Mr Otulana's total beneficial holding now amounts to 50,000 Ordinary Shares, which represents 0.01% of the issued share capital of the Company to which voting rights are attached.
�
Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them
|
1 � |
Details of the person discharging managerial responsibilities / person closely associated � |
|||||
|
a) � |
Name � � |
Babatunde (Tunde) Otulana� |
||||
|
2 � |
Reason for the notification � � |
|||||
|
a) � |
Position/status � � |
Non-Executive Director and PDMR |
||||
|
b) � |
Initial notification /Amendment � � |
Initial notification |
||||
|
3 � |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � |
|||||
|
a) � |
Name � � |
ALLERGY THERAPEUTICS PLC |
||||
|
b) � |
LEI � � |
213800PQ7AHK7KGVOE23 |
||||
|
4 � |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � |
|||||
|
a) � |
Description of the financial instrument, type of instrument � � � |
Ordinary Shares of �0.001 each � � � � � � |
||||
|
b) |
Identification code � |
GB00B02LCQ05 |
||||
|
c) � |
Nature of the transaction � � |
Purchase of Ordinary Shares |
||||
|
d) � |
Price(s) and volume(s) � � |
�
� � |
||||
|
e) � |
Aggregated information � � - Aggregated volume � � - Price � � |
� � � � � �25,000 Ordinary Shares � � $0.388 � � |
||||
|
f) � |
Date of the transaction � � |
15 March 2018 |
||||
|
g) � |
Place of the transaction � � |
United States |
||||
�
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
*calculated at a rate of GBP �1.00 to USD $1.3957, as at midday (GMT) 15 March 2018
�
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .